Bioventus Inc.
bioventus.comWhat Do They Do?
Sells pain treatments, surgical devices and bone-healing products to physicians, hospitals and patients.
10-K for FY2025, filed Mar 5, 2026We are a global medical device company focused on helping patients recover and live life to the fullest by relieving pain and addressing…View ↗
Pain Treatments, consisting of: Knee Osteoarthritis (“KOA”): Our product portfolio includes a range of intra-articular, hyaluronic acid…View ↗
We offer a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across…View ↗
Our Surgical Solutions portfolio is comprised of two patient-focused areas – Ultrasonics and Bone Graft Substitutes. Our Ultrasonics…View ↗
How Do They Make Money?
Bioventus sells medical products to healthcare institutions, providers, distributors and patients, generally at shipment or delivery; hospitals pay for consigned bone grafts when surgery uses them.
10-K for FY2025, filed Mar 5, 2026The Company derives revenue primarily from product sales in its (i) Pain Treatments portfolio, which includes osteoarthritic (“OA”) pain…View ↗
The Company recognizes revenue generally at a point in time upon transfer of control of the promised product to customers in an amount that…View ↗
Most of the Company’s product sales related to bone graft substitutes are through consignment inventory with hospitals, where ownership…View ↗
The Company consistently recognizes revenue from sales of its ultrasonic products in accordance with shipping terms. Control is transferred…View ↗
-
10-K for FY2025, filed Mar 5, 2026
FY2025 revenue by reportable segment ↗
$568.1M
-
10-K for FY2025, filed Mar 5, 2026
$568.1M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
U.S.
Sold outright
10-K for FY2025, filed Mar 5, 2026 |
88%
FY2022: 89%
|
U.S., FY2025
$502.1M Sources
|
Sold outright |
|
International
Sold outright
10-K for FY2025, filed Mar 5, 2026 |
12%
FY2022: 11%
|
International, FY2025
$66M Sources
|
Sold outright |
Who Are Their Customers?
Bioventus sells mainly through its direct sales team to healthcare providers, distribution centers and specialty pharmacies. Some surgical products reach hospitals through independent distributors, and international sales can also go through distributors.
10-K for FY2025, filed Mar 5, 2026We sell our products primarily through our direct sales team, which manages and maintains the sales relationship with healthcare providers…View ↗
Do Revenues Turn Into Profits?
Yes. It kept 4 cents of every revenue dollar as net income in FY2025 and turned 13 cents into free cash flow.
10-K for FY2025, filed Mar 5, 2026
$54MView ↗
10-K for FY2025, filed Mar 5, 2026
$22.7MView ↗
10-K for FY2025, filed Mar 5, 2026
$72.1MView ↗
How Are They Changing?
10-Q for Q2 FY2026, filed Aug 5, 2026
Open tableView ↗
-
Aug 5, 2026
Bioventus began a strategic review and reaffirmed full-year guidance
The review may include a sale or continuing as a standalone company after an unsolicited acquisition proposal and other expressions of interest.
Sources
8-K, filed Aug 5, 2026
As previously announced, following receipt of a recent unsolicited acquisition proposal from a party interested in acquiring the Company…View ↗
Growing. Revenue grew 32% in 4 years, from $430.9M in FY2021 to $568.1M in FY2025, about 7% a year.
Sports medicine products
The older report planned to expand beyond joint injections and nerve stimulation into sports medicine; the latest report describes U.S. distribution of the XCELL PRP System for orthopedic and sports medicine.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 5, 2026Continue to expand market share in Hyaluronic Acid (“HA”) viscosupplementation. We intend to increase sales of our HA viscosupplementation…View ↗
In 2025, we entered into an agreement with Apex Biologix to be the exclusive distributor of their XCELL PRP System in the United States…View ↗
Advanced rehabilitation
The older report included devices designed to help patients regain leg or hand function; the latest report says Bioventus sold certain Advanced Rehabilitation Business products and focused on core areas.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 5, 2026Pain Treatments is comprised of non-surgical joint pain injection therapies as well as peripheral nerve stimulation (“PNS”) products to…View ↗
On December 31, 2024, we completed the sale of certain products within our Advanced Rehabilitation Business, including the L100, L300 Go…View ↗
Who Do They Compete With?
Competes with Ferring Pharmaceutical, Fidia Farmaceutici, Johnson & Johnson, Zimmer Biomet Holdings, Arthrex, Emcyte, Channel-Markers Medical, SPR Therapeutics, Nalu, Curonix, Medtronic, DePuy Orthopaedics, Stryker, NuVasive, Orthofix Medical, Globus Medical, Integra Life Sciences, Söering, Enovis, and XFT Medical
10-K for FY2025, filed Mar 5, 2026Our Pain Treatments that we own or distribute compete with products from Ferring Pharmaceutical Inc., Fidia Farmaceutici S.p.A., Johnson &…View ↗
Loading...
